Kelly CRISPR & Gene Editing Tech ETF’s management team is just average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze. The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.
Morningstar’s Analysis XDNA
Will XDNA outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
Process Pillar
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings 23
- Bond Holdings 0
- Other Holdings 3
- % Assets in Top 10 Holdings 71.7